Here's Why BioMarin Pharmaceutical Leapt 10.2% in November

Shares of BioMarin Pharmaceutical (NASDAQ: BMRN) rose more than 10% last month, according to data from S&P Global Market Intelligence. The rare-disease specialist reported promising results from an ongoing phase 2 trial of an important drug candidate, held its annual research and development (R&D) day for investors, and submitted a marketing application for a gene therapy in the European Union.